Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis
NCT05389215 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 29, 2022
- Completion date
- January 30, 2027
- Enrollment
- 102 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.